Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease
Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial.Receiving Fast Track designation from the FDA will facilitate...
